Pharmacy World and Science

, Volume 23, Issue 4, pp 132–134 | Cite as

Long term therapy with spironolactone

  • Marcel L. BouvyEmail author
  • Eibert R. Heerdink
  • Ron M.C. Herings


Objective: to evaluate the duration of therapy with spironolactone in daily practice.Method: a retrospective follow‐up of a cohort of patients with a first prescription for spironolactone between January 1, 1990 and December 31, 1996 and at least one hospital discharge for CHF in the preceding year.Results: 243 patients met the inclusion criteria and were followed until the end of data collection. The average starting dosage of spironolactone was 55 mg. 143 patients (58.8%) discontinued spironolactone therapy before the end of follow‐up. 98 patients (40.8%) discontinued within 6 months of follow‐up. Of the 137 patients (56.4%) who did use spironolactone and an ACE‐inhibitor concomitantly, only 45 (32.8%) continued this combination until the end of follow‐up. The remainder of the patients discontinued either the ACE‐inhibitor (10.9%) or spironolactone (12.4%) or both (43.8%).Conclusion: while the reasons for discontinuation remain unclear, our data suggest that it is difficult to keep patients on both drugs. It is not certain whether these findings from past spironolactone use can be extrapolated to future use. Patients in the general population received higher average spironolactone dosages compared to the RALES study (55 mg vs. 26 mg), possibly resulting in more adverse effects and partly explaining the high discontinuation rate.

ACE‐inhibitors Cohort study Congestive Heart Failure Discontinuation Spironolactone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;34(10): 709-17.Google Scholar
  2. 2.
    Drug Interactions. 5th ed. London: The Pharmaceutical Press 1999.Google Scholar
  3. 3.
    Mooser V, Waeber G, Bidiville J, Waeber B, Nussberger J, Brunner HR. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic. J Clin Hypertens 1987;3(4):510-3.Google Scholar
  4. 4.
    Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27(9 Suppl):S1-24.Google Scholar
  5. 5.
    Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164(4):208-11.Google Scholar
  6. 6.
    Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311(7000):293-5.Google Scholar
  7. 7.
    Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther 1986;9(1):63-76.Google Scholar
  8. 8.
    Ikram H, Webster MW, Nicholls MG, Lewis GR, Richards AM, Crozier IG. Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. Aust N Z J Med 1986;16(1):61-3.Google Scholar
  9. 9.
    Dahlstrom U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 1993;71(3):29A-33A.Google Scholar
  10. 10.
    Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BCh, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158(10):1108-12.Google Scholar
  11. 11.
    Anonymous. ATC classification and DDD assignment. 1st edition ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 1996.Google Scholar
  12. 12.
    Bjorn M, Brendstrup C, Karlsen S, Carlsen JE. Consecutive screening and enrollment in clinical trials: the way to representative patient samples? J Card Fail 1998;4(3):225-30.Google Scholar
  13. 13.
    Massie BM, Cleland JG, Armstrong PW, Horowitz JD, Packer M, Poole-Wilson PA, et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail 1998;4(1):3-8.Google Scholar
  14. 14.
    Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ 1999;318(7178):234-7.Google Scholar
  15. 15.
    Rich MW, Gray DB, Beckham V, Wittenberg C, Luther P. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. Am J Med 1996;101(3):270-6.Google Scholar
  16. 16.
    Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;34(10):753-5.Google Scholar
  17. 17.
    Kehoe WA, Katz RC. Health behaviors and pharmacotherapy. Ann Pharmacother 1998;32(10):1076-86.Google Scholar
  18. 18.
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302.Google Scholar
  19. 19.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7.Google Scholar
  20. 20.
    Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999;159(16):1939-45.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Marcel L. Bouvy
    • 2
    Email author
  • Eibert R. Heerdink
    • 1
  • Ron M.C. Herings
    • 1
  1. 1.Department of Pharmacoepidemiology & Pharmacotherapy, Faculty of PharmacyUtrecht UniversityThe Netherlands
  2. 2.SIR Institute for Pharmacy Practice ResearchLeidenThe Netherlands

Personalised recommendations